Skip to main content
Top
Published in: Digestive Diseases and Sciences 8/2006

01-08-2006 | Original Paper

A Very Low-Carbohydrate Diet Improves Gastroesophageal Reflux and Its Symptoms

Authors: Gregory L. Austin, Michelle T. Thiny, Eric C. Westman, William S. Yancy Jr., Nicholas J. Shaheen

Published in: Digestive Diseases and Sciences | Issue 8/2006

Login to get access

Abstract

Obese patients with gastroesophageal reflux disease (GERD) may experience resolution of symptoms utilizing a very low-carbohydrate diet. The mechanism of this improvement is unknown. This studied aimed to prospectively assess changes in distal esophageal acid exposure and GERD symptoms among obese adults initiating a very low-carbohydrate diet. We studied obese individuals with GERD initiating a diet containing less than 20 g/day of carbohydrates. Symptom severity was assessed using the GERD Symptom Assessment Scale—Distress Subscale (GSAS-ds). Participants underwent 24-hr esophageal pH probe testing and initiated the diet upon its completion. Within 6 days, a second pH probe test was performed. Outcomes included changes in the Johnson-DeMeester score, percentage total time with a pH<4 in the distal esophagus, and GSAS-ds scores. Eight participants were enrolled. Mean Johnson-DeMeester score decreased from 34.7 to 14.0 (P=0.023). Percentage time with pH<4 decreased from 5.1% to 2.5% (P=0.022). Mean GSAS-ds score decreased from 1.28 to 0.72 (P=0.0004). These data suggest that a very low-carbohydrate diet in obese individuals with GERD significantly reduces distal esophageal acid exposure and improves symptoms.
Literature
1.
go back to reference Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd (1997) Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 112(5):1448–1456PubMedCrossRef Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd (1997) Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 112(5):1448–1456PubMedCrossRef
2.
go back to reference Sandler RS, Everhart JE, Donowitz M, et al. (2002) The burden of selected digestive diseases in the United States. Gastroenterology 122(5):1500–1511PubMedCrossRef Sandler RS, Everhart JE, Donowitz M, et al. (2002) The burden of selected digestive diseases in the United States. Gastroenterology 122(5):1500–1511PubMedCrossRef
3.
go back to reference Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd (1999) Risk factors associated with symptoms of gastroesophageal reflux. Am J Med 106(6):642–649PubMedCrossRef Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd (1999) Risk factors associated with symptoms of gastroesophageal reflux. Am J Med 106(6):642–649PubMedCrossRef
4.
go back to reference Nandurkar S, Locke GR, 3rd, Fett S, Zinsmeister AR, Cameron AJ, Talley NJ (2004) Relationship between body mass index, diet, exercise and gastro-oesophageal reflux symptoms in a community. Aliment Pharmacol Ther 20(5):497–505PubMedCrossRef Nandurkar S, Locke GR, 3rd, Fett S, Zinsmeister AR, Cameron AJ, Talley NJ (2004) Relationship between body mass index, diet, exercise and gastro-oesophageal reflux symptoms in a community. Aliment Pharmacol Ther 20(5):497–505PubMedCrossRef
5.
go back to reference Tutuian R, Castell DO (2003) Management of gastroesophageal reflux disease. Am J Med Sci 326(5):309–318PubMedCrossRef Tutuian R, Castell DO (2003) Management of gastroesophageal reflux disease. Am J Med Sci 326(5):309–318PubMedCrossRef
6.
go back to reference Kjellin A, Ramel S, Rossner S, Thor K (1996) Gastroesophageal reflux in obese patients is not reduced by weight reduction. Scand J Gastroenterol 31(11):1047–1051PubMedCrossRef Kjellin A, Ramel S, Rossner S, Thor K (1996) Gastroesophageal reflux in obese patients is not reduced by weight reduction. Scand J Gastroenterol 31(11):1047–1051PubMedCrossRef
7.
go back to reference Meining A, Classen M (2000) The role of diet and lifestyle measures in the pathogenesis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 95(10):2692–2697PubMedCrossRef Meining A, Classen M (2000) The role of diet and lifestyle measures in the pathogenesis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 95(10):2692–2697PubMedCrossRef
8.
go back to reference DeVault KR, Castell DO (2005) Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 100(1):190–200PubMedCrossRef DeVault KR, Castell DO (2005) Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 100(1):190–200PubMedCrossRef
9.
go back to reference Fraser-Moodie CA, Norton B, Gornall C, Magnago S, Weale AR, Holmes GK (1999) Weight loss has an independent beneficial effect on symptoms of gastro-oesophageal reflux in patients who are overweight. Scand J Gastroenterol 34(4):337–40PubMedCrossRef Fraser-Moodie CA, Norton B, Gornall C, Magnago S, Weale AR, Holmes GK (1999) Weight loss has an independent beneficial effect on symptoms of gastro-oesophageal reflux in patients who are overweight. Scand J Gastroenterol 34(4):337–40PubMedCrossRef
10.
go back to reference Yancy WS, Jr., Provenzale D, Westman EC (2001) Improvement of gastroesophageal reflux disease after initiation of a low-carbohydrate diet: five brief case reports. Altern Ther Health Med 7(6):120, 116–119PubMed Yancy WS, Jr., Provenzale D, Westman EC (2001) Improvement of gastroesophageal reflux disease after initiation of a low-carbohydrate diet: five brief case reports. Altern Ther Health Med 7(6):120, 116–119PubMed
11.
go back to reference Rothman M, Farup C, Stewart W, Helbers L, Zeldis J (2001) Symptoms associated with gastroesophageal reflux disease: development of a questionnaire for use in clinical trials. Dig Dis Sci 46(7):1540–1549PubMedCrossRef Rothman M, Farup C, Stewart W, Helbers L, Zeldis J (2001) Symptoms associated with gastroesophageal reflux disease: development of a questionnaire for use in clinical trials. Dig Dis Sci 46(7):1540–1549PubMedCrossRef
12.
go back to reference Damiano A, Handley K, Adler E, Siddique R, Bhattacharyja A (2002) Measuring symptom distress and health-related quality of life in clinical trials of gastroesophageal reflux disease treatment: further validation of the Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS). Dig Dis Sci 47(7):1530–1537PubMedCrossRef Damiano A, Handley K, Adler E, Siddique R, Bhattacharyja A (2002) Measuring symptom distress and health-related quality of life in clinical trials of gastroesophageal reflux disease treatment: further validation of the Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS). Dig Dis Sci 47(7):1530–1537PubMedCrossRef
13.
go back to reference Weusten B, Smout A (2004) Ambulatory monitoring of esophageal pH and pressure. In: Castell D, Richter J (eds) The esophagus, 4th ed. Lippincott, Williams, & Wilkins, Philadelphia, PA, pp 136–150 Weusten B, Smout A (2004) Ambulatory monitoring of esophageal pH and pressure. In: Castell D, Richter J (eds) The esophagus, 4th ed. Lippincott, Williams, & Wilkins, Philadelphia, PA, pp 136–150
14.
go back to reference Johnson LF, Demeester TR (1974) Twenty-four-hour pH monitoring of the distal esophagus. A quantitative measure of gastroesophageal reflux. Am J Gastroenterol 62(4):325–332PubMed Johnson LF, Demeester TR (1974) Twenty-four-hour pH monitoring of the distal esophagus. A quantitative measure of gastroesophageal reflux. Am J Gastroenterol 62(4):325–332PubMed
15.
go back to reference Streets CG, DeMeester TR (2003) Ambulatory 24-hr esophageal pH monitoring: why, when, and what to do. J Clin Gastroenterol 37(1):14–22PubMedCrossRef Streets CG, DeMeester TR (2003) Ambulatory 24-hr esophageal pH monitoring: why, when, and what to do. J Clin Gastroenterol 37(1):14–22PubMedCrossRef
16.
go back to reference Swiatkowski M, Budzynski J, Klopocka M, et al. (2004) The effect of eight weeks of rabeprazole therapy on nitric oxide plasma level and esophageal pH and motility and motility nitric oxide plasma level in patients with erosive esophagitis. Med Sci Monit 10(2):CR46–CR51PubMed Swiatkowski M, Budzynski J, Klopocka M, et al. (2004) The effect of eight weeks of rabeprazole therapy on nitric oxide plasma level and esophageal pH and motility and motility nitric oxide plasma level in patients with erosive esophagitis. Med Sci Monit 10(2):CR46–CR51PubMed
17.
go back to reference Ladas SD, Tassios PS, Raptis SA (2000) Selection of patients for successful maintenance treatment of esophagitis with low-dose omeprazole: use of 24-hr gastric pH monitoring. Am J Gastroenterol 95(2):374–380PubMed Ladas SD, Tassios PS, Raptis SA (2000) Selection of patients for successful maintenance treatment of esophagitis with low-dose omeprazole: use of 24-hr gastric pH monitoring. Am J Gastroenterol 95(2):374–380PubMed
18.
go back to reference Stern L, Iqbal N, Seshadri P, et al. (2004) The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trial. Ann Intern Med 140(10):778–785PubMed Stern L, Iqbal N, Seshadri P, et al. (2004) The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trial. Ann Intern Med 140(10):778–785PubMed
19.
go back to reference Yancy WS Jr, Olsen MK, Guyton JR, Bakst RP, Westman EC (2004) A low-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial. Ann Intern Med 140(10):769–777PubMed Yancy WS Jr, Olsen MK, Guyton JR, Bakst RP, Westman EC (2004) A low-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial. Ann Intern Med 140(10):769–777PubMed
20.
go back to reference El-Serag HB, Satia JA, Rabeneck L (2005) Dietary intake and the risk of gastro-oesophageal reflux disease: a cross sectional study in volunteers. Gut 54(1):11–17PubMedCrossRef El-Serag HB, Satia JA, Rabeneck L (2005) Dietary intake and the risk of gastro-oesophageal reflux disease: a cross sectional study in volunteers. Gut 54(1):11–17PubMedCrossRef
21.
go back to reference Wiener GJ, Morgan TM, Copper JB, et al. (1988) Ambulatory 24-hr esophageal pH monitoring. Reproducibility and variability of pH parameters. Dig Dis Sci 33(9):1127–1133PubMedCrossRef Wiener GJ, Morgan TM, Copper JB, et al. (1988) Ambulatory 24-hr esophageal pH monitoring. Reproducibility and variability of pH parameters. Dig Dis Sci 33(9):1127–1133PubMedCrossRef
22.
go back to reference Vaezi MF, Schroeder PL, Richter JE (1997) Reproducibility of proximal probe pH parameters in 24-hr ambulatory esophageal pH monitoring. Am J Gastroenterol 92(5):825–829PubMed Vaezi MF, Schroeder PL, Richter JE (1997) Reproducibility of proximal probe pH parameters in 24-hr ambulatory esophageal pH monitoring. Am J Gastroenterol 92(5):825–829PubMed
23.
go back to reference Piche T, Zerbib F, Varannes SB, et al. (2000) Modulation by colonic fermentation of LES function in humans. Am J Physiol Gastrointest Liver Physiol 278(4):G578–G584PubMed Piche T, Zerbib F, Varannes SB, et al. (2000) Modulation by colonic fermentation of LES function in humans. Am J Physiol Gastrointest Liver Physiol 278(4):G578–G584PubMed
24.
go back to reference Piche T, des Varannes SB, Sacher-Huvelin S, Holst JJ, Cuber JC, Galmiche JP (2003) Colonic fermentation influences lower esophageal sphincter function in gastroesophageal reflux disease. Gastroenterology 124(4):894–902PubMedCrossRef Piche T, des Varannes SB, Sacher-Huvelin S, Holst JJ, Cuber JC, Galmiche JP (2003) Colonic fermentation influences lower esophageal sphincter function in gastroesophageal reflux disease. Gastroenterology 124(4):894–902PubMedCrossRef
25.
go back to reference Clave P, Gonzalez A, Moreno A, et al. (1998) Endogenous cholecystokinin enhances postprandial gastroesophageal reflux in humans through extrasphincteric receptors. Gastroenterology 115(3):597–604PubMedCrossRef Clave P, Gonzalez A, Moreno A, et al. (1998) Endogenous cholecystokinin enhances postprandial gastroesophageal reflux in humans through extrasphincteric receptors. Gastroenterology 115(3):597–604PubMedCrossRef
26.
go back to reference Zerbib F, Bruley DesVarannes S, et al. (1998) Endogenous cholecystokinin in postprandial lower esophageal sphincter function and fundic tone in humans. Am J Physiol 275(6, Pt 1):G1266–G1273PubMed Zerbib F, Bruley DesVarannes S, et al. (1998) Endogenous cholecystokinin in postprandial lower esophageal sphincter function and fundic tone in humans. Am J Physiol 275(6, Pt 1):G1266–G1273PubMed
27.
go back to reference Ledeboer M, Masclee AA, Batstra MR, Jansen JB, Lamers CB (1995) Effect of cholecystokinin on lower oesophageal sphincter pressure and transient lower oesophageal sphincter relaxations in humans. Gut 36(1):39–44PubMedCrossRef Ledeboer M, Masclee AA, Batstra MR, Jansen JB, Lamers CB (1995) Effect of cholecystokinin on lower oesophageal sphincter pressure and transient lower oesophageal sphincter relaxations in humans. Gut 36(1):39–44PubMedCrossRef
28.
go back to reference Straathof JW, Tieleman S, Lamers CB, Masclee AA (2000) Effect of somatostatin on lower esophageal sphincter characteristics in man. Scand J Gastroenterol 35(9):910–915PubMedCrossRef Straathof JW, Tieleman S, Lamers CB, Masclee AA (2000) Effect of somatostatin on lower esophageal sphincter characteristics in man. Scand J Gastroenterol 35(9):910–915PubMedCrossRef
29.
go back to reference Lidums I, Lehmann A, Checklin H, Dent J, Holloway RH (2000) Control of transient lower esophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in normal subjects. Gastroenterology 118(1):7–13PubMedCrossRef Lidums I, Lehmann A, Checklin H, Dent J, Holloway RH (2000) Control of transient lower esophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in normal subjects. Gastroenterology 118(1):7–13PubMedCrossRef
30.
go back to reference Stacher G, Lenglinger J, Bergmann H, et al. (2000) Gastric emptying: A contributory factor in gastro-oesophageal reflux activity? Gut 47(5):661–666PubMedCrossRef Stacher G, Lenglinger J, Bergmann H, et al. (2000) Gastric emptying: A contributory factor in gastro-oesophageal reflux activity? Gut 47(5):661–666PubMedCrossRef
31.
go back to reference Buckles DC, Sarosiek I, McMillin C, McCallum RW (2004) Delayed gastric emptying in gastroesophageal reflux disease: reassessment with new methods and symptomatic correlations. Am J Med Sci 327(1):1–4PubMedCrossRef Buckles DC, Sarosiek I, McMillin C, McCallum RW (2004) Delayed gastric emptying in gastroesophageal reflux disease: reassessment with new methods and symptomatic correlations. Am J Med Sci 327(1):1–4PubMedCrossRef
Metadata
Title
A Very Low-Carbohydrate Diet Improves Gastroesophageal Reflux and Its Symptoms
Authors
Gregory L. Austin
Michelle T. Thiny
Eric C. Westman
William S. Yancy Jr.
Nicholas J. Shaheen
Publication date
01-08-2006
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 8/2006
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-005-9027-7

Other articles of this Issue 8/2006

Digestive Diseases and Sciences 8/2006 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.